The capital raise also needs shareholder approval. A capital raise may get approved with some adjustments. Issuing Options may not be part of the deal. If the company is going to increase revenues Options aren't a good idea, more dilutive.
The contingency to adjust the price down may have been due to the possibility of the FDA Approval being delayed. It was expected in March.
Ann: FDA Approval for Xprecia Prime, page-35
-
- There are more pages in this discussion • 79 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add UBI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
15.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $44.71M | |||
| Open | High | Low | Value | Volume |
| 15.0¢ | 16.0¢ | 15.0¢ | $80.63K | 526.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 642508 | 15.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.0¢ | 3734 | 2 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| UBI (ASX) Chart |